HGG

NeoImmuneTech Presents Phase 1 Study Data at Society for Neuro-Oncology Annual Meeting

Retrieved on: 
Monday, November 22, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Patient, Mayo Clinic, Pakistan Society of Neuro-Oncology, Safety, Eli Lilly, Countersurveillance, Industry, PricewaterhouseCoopers, BMS, TMZ, Company, Novartis, Population, GBM, Cancer, Chemoradiotherapy, KOSDAQ, Amgen, Temozolomide, Progression-free survival, NIT, GSK, ALC, Society, Immunity, IL-7, SNO, HGG, Infection, Pharmaceutical industry, Vaccine

NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today presented data from Phase 1 of an ongoing study at the Society for Neuro-Oncology (SNO) annual meeting.

Key Points: 
  • NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today presented data from Phase 1 of an ongoing study at the Society for Neuro-Oncology (SNO) annual meeting.
  • The data show that NT-I7, a novel long-acting human IL-7, was well tolerated following chemoradiation in patients with high-grade gliomas (HGG), supporting continued evaluation in the Phase 2 portion of the study.
  • The median progression-free survival for MGMTp unmethylated GBM was 11.6 months, compared to 5.3 months commonly reported in chemoradiation studies.
  • Some of the data contained in these documents were obtained from various external sources, and the Company has not independently verified such data.

Cellectar’s Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors

Retrieved on: 
Tuesday, November 16, 2021
Osteosarcoma, Safety, HGG, Diffuse intrinsic pontine glioma, Cancer, Pediatric ependymoma, News, Sarcoma, Neoplasm, European Commission, Exchange, Security (finance), NASDAQ, B-cell lymphoma, DMC, Outline, Food, Ewing's sarcoma, Glioblastoma, Odds, Brain, COVID-19, MM, Research, DLBCL, Regulation, Astrocytoma, Twitter, Multiple myeloma, Neuroblastoma, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, GLOBE, WM, LinkedIn, Collection, Rhabdomyosarcoma, Drug discovery, Christian democracy, Survival, PDC, Central nervous system, Marketing, PFS, Patient, Risk, FDA, Lymphoma, Pharmaceutical industry, Medical imaging

Initial responses to iopofosine I-131 in relapsed pediatric brain tumors are most encouraging.

Key Points: 
  • Initial responses to iopofosine I-131 in relapsed pediatric brain tumors are most encouraging.
  • Pediatric HGGs are a collection of aggressive brain and central nervous system tumor subtypes including diffuse intrinsic pontine gliomas, glioblastomas, astrocytomas and ependymomas.
  • Iopofosine is currently being evaluated in the CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstroms macroglobulinemia (WM), a Phase 2b study in r/r multiple myeloma (MM) patients and the CLOVER-2 Phase 1 study for a variety of pediatric cancers.
  • The company is also evaluating iopofosine in highly refractory multiple myeloma patients in its Phase 2 CLOVER-1 study and relapsed/refractory pediatric cancer patients with sarcomas or brain tumors in the Phase 1 CLOVER-2 study.

NeoImmuneTech Presents Data in Three Posters at Society for Immunotherapy of Cancer Annual Meeting

Retrieved on: 
Tuesday, November 16, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Chemoradiotherapy, NIT, SITC, Immunity, TMZ, Progression-free survival, Cancer, Industry, Novartis, Long-acting reversible contraception, Countersurveillance, Infection, Radiation, University, Merck, Clinical data management system, KOSDAQ, Temozolomide, Blood, Society, Pembrolizumab, NK, ALC, Eli Lilly, BMS, Tumor microenvironment, MD Anderson Cancer Center, IPR, IL-7, CPI, Society for Immunotherapy of Cancer, Neoplasm, Company, Merck Sharp & Dohme Federal Credit Union, Pancreatic cancer, Mayo Clinic, ORR, Immunotherapy, CD8, H. Lee Moffitt Cancer Center & Research Institute, PricewaterhouseCoopers, Poster, PFS, Patient, GSK, HGG, Merck & Co., RECIST, Amgen, Pharmaceutical industry, Medical imaging, Vaccine

NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today presented new data from two clinical trials evaluating the companys lead asset NT-I7 (efineptakin alfa), a novel T cell amplifier, in three posters at the Society for Immunotherapy of Cancer (SITC) annual meeting.

Key Points: 
  • NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today presented new data from two clinical trials evaluating the companys lead asset NT-I7 (efineptakin alfa), a novel T cell amplifier, in three posters at the Society for Immunotherapy of Cancer (SITC) annual meeting.
  • The interim analysis of the phase 2 met the primary endpoint of overall response rate (ORR) in these cohorts.
  • The median follow-up of the efficacy data was ~5.8 months in the MSS-CRC Cohort and ~4.6 months in the Pancreatic Cancer Cohort.
  • Some of the data contained in these documents were obtained from various external sources, and the Company has not independently verified such data.

Candel Therapeutics Presents Novel Biomarker Data Demonstrating Immune Activation After Administration of CAN-3110 in Patients with Recurrent High-Grade Glioma

Retrieved on: 
Friday, November 12, 2021
Society, Population, SITC, Cancer, Private Securities Litigation Reform Act, Therapy, ICP34.5, MD, Chemokine, Neoplasm, Cytokine, Immunogenic cell death, HSV, Doctor of Philosophy, CADL, Trial of the century, Tumor microenvironment, American Society of Clinical Oncology, Histology, Annual general meeting, Company, GLOBE, Mace Head Atmospheric Research Station, Immunology, SEC, ASCO, Nestin, Survival, Nasdaq, Patient, HGG, Adult, Vaccine, Pharmaceutical industry

During the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2021, Candel reported preliminary clinical data demonstrating an overall survival of 11.7 months in this difficult-to-treat patient population.

Key Points: 
  • During the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2021, Candel reported preliminary clinical data demonstrating an overall survival of 11.7 months in this difficult-to-treat patient population.
  • These findings collectively indicate that CAN-3110 treatment can induce both local and systemic immune activation associated with an encouraging clinical response.
  • There is a critical need for treatment options for patients with recurrent high-grade glioma.
  • Candel has established two oncolytic viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Brain Cancer Canada Funds Canadian Research Aiming To Treat Brain Cancer

Retrieved on: 
Sunday, October 24, 2021
Canada, Cancer, Research, Quality of life, Technology, RAS, DRS, Brain tumor, Growth hacking, Child, Patient, Brain, HGG, Adult, Glioblastoma, ISCB Senior Scientist Award, Hospital for Sick Children (Toronto), Cell biology, GLOBE, The Hospital, Pharmaceutical industry, Medical imaging

TORONTO, Oct. 24, 2021 (GLOBE NEWSWIRE) -- Brain Cancer Canada has issued a $100,000 grant to Canadian research exploring new frontiers of brain cancer treatment.

Key Points: 
  • TORONTO, Oct. 24, 2021 (GLOBE NEWSWIRE) -- Brain Cancer Canada has issued a $100,000 grant to Canadian research exploring new frontiers of brain cancer treatment.
  • Less than 3% of all governmental cancer funding is devoted to brain cancer research.
  • "We remain strongly committed to supporting the fight against high-grade gliomas by funding research, treatment and technology," said Brain Cancer Canada chair Angela Scalisi.
  • To learn more about Brain Cancer Canada, please visit www.braincancercanada.ca
    For inquiries, please contact: Marc Peeters, Director Partnerships and Stakeholders at Brain Cancer Canada, [email protected], 416 918 6678

KIYATEC Announces Addition of Chief Commercial Officer Stacy Chick to Executive Team

Retrieved on: 
Tuesday, September 21, 2021
Electronic Design Automation, Oncology, Health, Technology, General Health, Biotechnology, Glioma, Glioblastoma, Breast, Neoplasm, Policy, Partnership, Oncology, Multimedia, Patient, HGG, Physician, Hotel manager, Marketing, CO, Leadership, Trial of the century, 3D, Technology, Drug development, CCO, Medical imaging

The functional precision oncology company KIYATEC, Inc. announced today the addition of Chief Commercial Officer, Stacy Chick, to their Executive Team.

Key Points: 
  • The functional precision oncology company KIYATEC, Inc. announced today the addition of Chief Commercial Officer, Stacy Chick, to their Executive Team.
  • Most recently, Stacy served as US Commercial Advisor to several global life sciences companies, investors, and boards.
  • As CCO at KIYATEC she is responsible for building and leading the commercial strategies for clinical testing, beginning with the 3D PredictTM tests.
  • Matthew Gevaert, KIYATEC CEO and Co-founder said, We welcome Stacy to our team and are enthusiastic about the commercial launches of the 3D Predict tests under her remarkable leadership.

Plus Therapeutics Announces Presentation of Data from the ReSPECT™-GBM Trial and Plans for Treating Pediatric Brain Cancer

Retrieved on: 
Saturday, August 21, 2021
Lurie, RNL, Company, Cancer, DIPG, Feinberg School of Medicine, CNS, Nasdaq, U.S. Securities and Exchange Commission, Convection, American Association of Neurological Surgeons, GLOBE, Regulation, Nanotechnology, Research, Diffuse intrinsic pontine glioma, AANS, Tissue, EBRT, Doctor of Philosophy, Therapy, Perception, American Association, Radiation, Plus, Intellectual property, HGG, Â, GBM, Brain, IND, Adult, Safety, Risk, CED, Partnership, Patient, PSTV, NIH, Association, FDA, Neoplasm, COVID-19, Part, Drug development, Medical imaging, Pharmaceutical industry

AUSTIN, Texas, Aug. 21, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today presented data from the NIH-supported ReSPECTTM Phase 1 clinical trial evaluating its lead investigational drug, Rhenium-186 NanoLiposome (186RNL), in recurrent glioblastoma (GBM). Data from the trial shows that the administration of 186RNL, which is designed to allow for targeted beta radiation to the tumor via convection enhanced delivery (CED) with limited exposure to surrounding tissues, was well tolerated in adult patients with recurrent GBM at significantly higher doses than with standard treatment modalities such as external beam radiation therapy (EBRT).

Key Points: 
  • Children with brain tumors have limited options and 186RNL delivered with a minimally invasive procedure could be an important new potential option for these patients.
  • Additional key findings from ReSPECT clinical trial for adult recurrent GBM:
    The treatment has been well tolerated, with no dose-limiting toxicity or serious adverse events observed (n=18).
  • We are eager to explore the use of 186RNL in children with pediatric brain tumors of various types, stated Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics.
  • Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets.

Plus Therapeutics to Present Data from ReSPECT™-GBM Trial at the American Association of Neurological Surgeons 2021 Annual Scientific Meeting

Retrieved on: 
Friday, August 13, 2021
PSTV, AANS, Neurology, Intellectual property, Nasdaq, RNL, Regulation, Clinical trial, Diffuse intrinsic pontine glioma, Perception, Convection, HGG, Drug development, Company, DIPG, American Association, Cancer, COVID-19, Therapy, Partnership, IND, GLOBE, Nanotechnology, Risk, U.S. Securities and Exchange Commission, Research, Doctor of Philosophy, FDA, Plus, Feinberg School of Medicine, Patient, CNS, GBM, Association, Radiation, Safety, Pharmaceutical industry

AUSTIN, Texas, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the Company), a clinical-stage pharmaceutical company developing innovative, targeted therapies for rare and difficult-to-treat cancers, today announced it will present data on Rhenium-186 NanoLiposome (186RNL) from its Phase 1 ReSPECTclinical trial in recurrent glioblastoma (GBM) at the American Association of Neurological Surgeons 2021 Annual Scientific Meeting (AANS) being held virtually August 21-25, 2021.

Key Points: 
  • AUSTIN, Texas, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the Company), a clinical-stage pharmaceutical company developing innovative, targeted therapies for rare and difficult-to-treat cancers, today announced it will present data on Rhenium-186 NanoLiposome (186RNL) from its Phase 1 ReSPECTclinical trial in recurrent glioblastoma (GBM) at the American Association of Neurological Surgeons 2021 Annual Scientific Meeting (AANS) being held virtually August 21-25, 2021.
  • Central to the Companys drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases.
  • This press release contains statements that may be deemed forward-looking statements within the meaning of U.S. securities laws.
  • All statements in this press release other than statements of historical fact are forward-looking statements.